IMMY Insider Trading Activity and SEC Form 4 Filings
IMMY insider trading summary
No open-market insider purchases or sales of Imprimis Pharmaceuticals, Inc. (IMMY) have been reported on SEC Form 4 in the past 12 months.
Latest IMMY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 3, 2018 | Robert J Kammer | Director | Sell | $46K (10,000 @ $4.64) |
| Nov 1, 2018 | Robert J Kammer | Director | Sell | $42K (10,000 @ $4.21) |
| Oct 15, 2018 | Robert J Kammer | Director | Sell | $30K (10,000 @ $3.00) |
| Sep 4, 2018 | Robert J Kammer | Director | Sell | $30K (10,000 @ $3.00) |
| Aug 10, 2018 | Robert J Kammer | Director | Sell | $390K (130,000 @ $3.00) |
| Jul 17, 2017 | Robert J Kammer | Director | Sell | $31K (10,000 @ $3.05) |
| Dec 19, 2016 | Andrew R. Boll | Chief Financial Officer | Buy | $70K (39,000 @ $1.79) |
| Dec 19, 2016 | Richard L Md Lindstrom | Director | Buy | $179K (100,000 @ $1.79) |
| Dec 19, 2016 | Mark L Baum | Chief Executive Officer | Buy | $279K (156,000 @ $1.79) |
| Mar 11, 2016 | Opaleye Management Inc. | 10% Owner | Buy | $164K (45,000 @ $3.65) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.